683 Capital Management’s Roivant Sciences ROIV Stock Holding History

683 Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-261,000	Closed	-$3.01M	–	232
2024 Q3	$3.01M	Sell	261,000 -149,000	-36%	-$1.7M	0.23%	79
2024 Q2	$4.33M	Buy	410,000 +139,866	+52%	+$1.53M	0.33%	65
2024 Q1	$2.85M	Buy	270,134 +9,134	+3%	+$98.5K	0.21%	74
2023 Q4	$2.93M	Buy	+261,000	New	+$2.54M	0.24%	74

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

683 Capital Management's ROIV Position: Q4 2024 in Review

683 Capital Management sold out of Roivant Sciences (ROIV) in Q4 2024, closing a stake of 261,000 shares — an estimated $3.01M sold.

683 Capital Management first reported a position in ROIV in Q4 2023 and held it in 4 quarters. The position peaked at $4.33M in Q2 2024. 318 funds tracked by Wall St. Rank hold ROIV as of Q4 2024.

683 Capital Management reported no remaining Roivant Sciences position as of Q4 2024 after selling out during the quarter.
683 Capital Management sold 261,000 Roivant Sciences shares in Q4 2024, an estimated $3.01M.
683 Capital Management first reported a position in Roivant Sciences in Q4 2023 and held it in 4 quarters.
683 Capital Management's Roivant Sciences position peaked at $4.33M in Q2 2024.
318 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2024.

Based on 683 Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.